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SUMMARY Different clinical studies report the connection between 
malignant melanoma (MM) and vitiligo, as the etiology of both 
diseases evolves around melanocytes. A case is presented of a 
70-year-old female patient with metastatic MM in lymphatic node 
of the right groin, which developed simultaneously with the “vitiligo-
like patches” over the face and extremities. Some authors suggest 
that the appearance of depigmentation during the course of MM 
might be considered a good prognostic sign. However, our patient 
subsequently developed multiple lung metastases as well as 
metastases in lymphatic nodes of the other groin region. This case 
shows that MM and vitiligo may develop simultaneously, indicating 
the possibility of similar mechanisms in the destruction of both 
benign and malignant melanocytes.
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INTRODUCTION
 Malignant melanoma (MM) is a cancer of mela-
nocytes, which can sometimes develop simultane-
ously with vitiligo, a depigmenting disorder with the 
loss of melanocytes from the epidermis. Healthy 
skin contains melanin produced from the amino 
acid tyrosine by skin melanocytes, but in the skin 
affected by vitiligo, melanocytes are absent and 
there are signs of inflammation in the deeper layer 
of the skin (1,2).
 Several clinical observations suggest that there 
is a certain immunological link between MM and 
vitiligo (3,4). However, the nature of immune dis-
turbances associated with these diseases is yet 
not elucidated (4,5).
 We present a case of a 70-year-old female pa-
tient with metastatic MM in lymphatic node of the 
right groin, which developed simultaneously with 
the “vitiligo-like patches” over the face and ex-
tremities.
CASE REPORT
 A 70-year-old female Caucasian was referred 
to our department after biopsy of a brown reddish 
inflamed node in the right groin region. Histopath-
ologic examination of the node showed connec-
tive and fatty tissue infiltrated with tumor cells. The 
tumor consisted of  clusters of polygonal cells with 
prominent nucleoli and a substantial quantity of 
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cytoplasmic melanin showing high mitotic activity 
with up to 5 mitoses per high-power field (HPF), 
indicating metastatic MM (Fig. 1). 
 In spite of thorough clinical examination of the 
skin and mucous membranes, primary melanoma 
had never been discovered. Unfortunately, our pa-
tient subsequently developed multiple lung metas-
tases as well as metastases in lymphatic nodes of 
the other groin region.
 Previous patient’s medical history included 
hysterectomy 18 years before (due to myomatous 
uterus), and cholecystectomy 8 years ago and, 
was otherwise unremarkable. It was also reported 
that the patient had been spending a lot of time in 
the sun, working in the field. The patient’s family 
medical history included frequent non-skin can-
cers.
DISCUSSION
 A variety of arguments obtained from clinical 
observations support the hypothesis that autoim-
munity is important for the development of both 
MM and vitiligo. Although the cause of vitiligo has 
not yet been elucidated, there are three major hy-
potheses: autoimmune, neural and self-destruc-
tion hypothesis (1,2,6). Probably each of them 
plays a role in individual cases, however, there 
are convincing scientific arguments both for and 
against each hypothesis.
 The autoimmune hypothesis of vitiligo implies 
an autoimmune reaction against melanocytes 
during the process of their normal turnover in the 
basal layer with the development of cytotoxic re-
actions and subsequent destruction of normal me-
lanocytes (1,7). Many autoantibodies have been 
demonstrated in vitiligo patients, but those against 
melanocytes are among the hardest ones to find. 
Despite specific autoantibodies against melano-
cytes found in the blood of vitiligo patients, it is not 
known whether autoantibodies are the cause or 
the effect of the damage. 
 Some studies showed most patients with mela-
noma or with vitiligo to develop antibodies to simi-
lar antigens present both on melanocytes and on 
melanoma cells, supporting the hypothesis that 
the clinical link between these two diseases may 
be the result of immune responses to antigens 
shared by both normal and malignant pigment 
cells (5). The enzyme tyrosinase participates in 
melanin production in normal melanocytes and 
melanoma cells, thus the detection of antityrosi-
nase antibodies in patients with vitiligo and mela-
noma supports the hypothesis that tyrosinase may 
be an autoantigen in these conditions (8).  
 Neural hypothesis for the development of vitili-
go is based on the fact that vitiligo lesions often fol-
Figure 1. Connective and fatty tissue infiltrated 
with tumor made up of  clusters of polygonal cells 
with prominent nucleoli and a substantial quantity 
of cytoplasmic melanin showing high mitotic activ-
ity of up to 5 mitoses per high-power field (HPF), 
indicating metastatic melanoma (HE, x400).
 According to history data, at the same time when 
the inflamed node in the right groin appeared, the 
patient noticed emerging of small, multiple, well-
demarcated, confluent depigmented patches over 
both wrists and dorsal sides of fingers. Depigment-
ed macular lesions also spread gradually over the 
face during the period of 4 months, followed by the 
affection of groins and lower legs (Fig. 2). 
Figure. 2. Multiple, well-demarcated, confluent, 
depigmented patches over the face, both wrists 
and dorsal sides of fingers in the patient with his-
topathologically verified metastatic melanoma in 
lymphatic node of the right groin. 
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low a dermatomal pattern, suggesting that a neu-
rochemical mediator is responsible for destruction 
of melanocytes. This fact indicates an association 
of nerve damage with the loss of pigment in the 
skin area served by the nerve. However, the dis-
tribution of depigmented patches in our patient did 
not correspond to dermatomal pattern.
 Self-destruction hypothesis of vitiligo develop-
ment is based on the assumption that toxic inter-
mediatory products of melanin synthesis destroy 
melanocytes (1). 
 There are several reports on the appearance of 
’’vitiligo-like patches’’ on the skin of patients with 
MM, called melanoma-associated hypopigmenta-
tion (MAH) (8). Several types of hypomelanosis 
may occur in patients with MM (9). The loss of 
pigmentation may involve the primary lesion itself 
(the form of an eccentrically placed hypopigment-
ed macule, analogous to halo nevus), or it may 
occur in distant locations (a process known as 
melanoma-associated leukoderma). Unfortunate-
ly, primary melanoma has never been diagnosed 
in our patient. Therefore, it remains questionable 
whether in this case the loss of pigmentation in-
cluded the primary lesion itself or it occurred in a 
distant location.
 Furthermore, leukoderma may be hypomela-
notic and mottled, or depigmented and milk-white. 
In some cases spontaneous repigmentation may 
occur. Clinically, it is frequently first observed on 
the trunk, with subsequent spread to extremities. 
On the contrary, our patient’s depigmenting pro-
cess began on the extremities, followed by the af-
fection of the face.
 The leukoderma observed in MM patients may 
develop as the result of an immune response 
against abnormal melanocytes. Some authors 
suggest that the appearance of depigmentation 
during the course of MM might be considered a 
good prognostic sign (3,5,9,10). On the other 
hand, our patient subsequently developed mul-
tiple lung metastases as well as metastases in 
lymphatic nodes of the other groin region. 
 Furthermore, one study in which the sera of pa-
tients with vitiligo, melanoma, MAH, and of healthy 
subjects were examined, defined antibodies to the 
B16 melanoma cell line and to tyrosinase, indicat-
ing the cross-antigenicity between melanocytes 
and melanoma cells (11). These results support 
the hypothesis on the participation of antibodies 
against melanoma-associated membrane anti-
gens in the mechanism that leads to the develop-
ment of MAH. 
 Besides humoral immunity, the role of cellular 
immunity in vitiligo was confirmed by histological 
and immunohistochemical studies in perilesion-
al skin, and T-cell analyses in peripheral blood 
(7,12). 
 It has been observed that some factors found 
in melanoma patient sera contribute to the impair-
ment of cytotoxicity, whereas other factors from 
the serum of vitiligo patients and control subjects 
enhanced their peripheral blood mononuclear cell 
antimelanoma cytotoxicity (4). 
 Examination of spontaneous vitiligo in human 
melanoma and animal model revealed the role 
of tumor-specific CD8(+) T cells (10). Namely, tu-
mor antigen-reactive T cells can be detected in a 
large proportion of MM patients, in spite of their 
unclear efficacy on tumor control in vivo. It has 
also been noticed that immunologic destruction of 
tumors including melanoma is mediated primarily 
by activated T cells exerting this effect by recog-
nizing peptides derived from endogenous proteins 
(3,13). These proteins may be either antigens en-
coded by tumor-specific or mutated genes, or me-
lanocytic differentiation antigens, which are nor-
mal proteins restricted to the melanocyte lineage, 
such as tyrosinase, Melan-A/MART-1, and gp 100. 
In the majority of melanoma patients T cells spe-
cific to these antigens were found. T cells involved 
in the destruction of neoplastic melanocytes are 
identical clones of those that accumulate in mela-
noma-associated leukoderma, thus indicating the 
association between vitiligo-like leukoderma (re-
sulting from destruction of normal melanocytes) 
and melanoma regression (resulting from destruc-
tion of cancer cells) (9).
CONCLUSIONS
 Although some authors suggest that simultane-
ous occurrence of melanoma and skin depigmen-
tation often presents a good prognostic sign, our 
case warns about the possibility of poor outcome, 
especially when it is impossible to detect primary 
melanoma. This case indicates the importance of 
an early and detailed examination of vitiligo pa-
tients, since both vitiligo and melanoma are dis-
eases based on melanocytic changes which in 
case of melanoma may be fatal.
 Despite many unknown mechanisms, under-
standing the nature of immune responses directed 
against normal melanocytes and their malignant 
counterparts may lead to better understanding of 
the mechanisms and factors involved in the patho-
genesis of both vitiligo and melanoma.
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For skin protection in the spring – Nivea cream and oil, year 1935.
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